MIST3: Active Patient Safety Reporting

This study will seek to describe and understand adverse events (AE) severity ratings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Safety Issues

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Parker University

Dallas, Texas, 75229, United States

About this study

Using an explanatory mixed methods design, three different quantitative methods 1. severity ratings based on a series of questions, 2. severity rating based on severity terms, and 3. severity based on definitions will be used to conduct a feasibility study on understanding adverse event reporting system.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Health patients

Exclusion criteria

None

Treatment and study plan

Primary outcomes

Pre-screening questionnaire

Time frame: 5-10 minute

Severity rating based on a series of questionnaire
Post-survey

Time frame: Immediately after visit

Severity rating based on severity term questionnaire
follow-up questionnaire

Time frame: 7-10 days after visit

Severity rating based on definitions questionnaire

Sponsors and collaborators

Lead sponsor

Parker University

Other

Registry information

Official study title

Mitigation Investigation for Spinal Manipulation Treatments (MIST) - Part 3: Continued Assessment & Feasibility of an Electronic Active Surveillance Reporting System

Acronym: MIST3

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Nov 13, 2019
Registry last updated: Feb 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed